Medchew-1502

**Medchew-1502** is a pharmaceutical chewing gum formulation developed as a cannabinoid-based therapeutic, functioning as a **CB agonist** to target neurological conditions. It is designed for buccal delivery via medicated chewing gum (MCG), providing extended-release and rapid absorption through the oral mucosa to minimize gastric issues. Initially developed by **AXIM Biotechnologies**, the asset was acquired by **Incannex Healthcare** through its purchase of **APIRx Pharmaceuticals** in 2022, with **APIRx** founders **George Anastassov** and **Lekhram Changoer** leading development. Primary indication is **Parkinson's disease**, with preclinical status including FDA Pre-IND clearance; it leverages proprietary cannabinoid patents for conditions like pain and neurological disorders.[1][2][8]

Brand names

MedChew-1502MedChew1502MedChew 1502